Terms: = Bone cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
26 results:
1. Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.
Thill M; Zahn MO; Welt A; Stickeler E; Nusch A; Fietz T; Rauh J; Wetzel N; Kruggel L; Jänicke M; Marschner N; Harbeck N; Wöckel A; Decker T;
Breast Cancer Res Treat; 2023 Apr; 198(3):545-553. PubMed ID: 36807725
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic effect of low-level her2 expression in patients with clinically negative her2 status.
Hein A; Hartkopf AD; Emons J; Lux MP; Volz B; Taran FA; Overkamp F; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wurmthaler LA; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Kurbacher CM; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A; Kolberg HC
Eur J Cancer; 2021 Sep; 155():1-12. PubMed ID: 34311211
[TBL] [Abstract] [Full Text] [Related]
3. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/her2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]
4. Luminal B breast cancer: patterns of recurrence and clinical outcome.
Li ZH; Hu PH; Tu JH; Yu NS
Oncotarget; 2016 Oct; 7(40):65024-65033. PubMed ID: 27542253
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract] [Full Text] [Related]
6. Pattern of metastasis and outcome in patients with breast cancer.
Gerratana L; Fanotto V; Bonotto M; Bolzonello S; Minisini AM; Fasola G; Puglisi F
Clin Exp Metastasis; 2015 Feb; 32(2):125-33. PubMed ID: 25630269
[TBL] [Abstract] [Full Text] [Related]
7. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
[TBL] [Abstract] [Full Text] [Related]
8. Pathological features and prognosis of lobular carcinoma in Egyptian breast cancer patients.
Azim HA; Malek RA; Azim HA
Womens Health (Lond); 2014 Sep; 10(5):511-8. PubMed ID: 25335542
[TBL] [Abstract] [Full Text] [Related]
9. Survival of patients with metastatic breast cancer: a single-centre experience.
D'hondt R; Spoormans I; Neyens N; Mortier N; Van Aelst F
Acta Clin Belg; 2014 Jun; 69(3):194-9. PubMed ID: 24641516
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome in women with her2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract] [Full Text] [Related]
11. her2/CEP17 ratio and her2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with her2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract] [Full Text] [Related]
12. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
[TBL] [Abstract] [Full Text] [Related]
13. Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact.
Dhakal HP; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Bassarova A; Holm R; Giercksky KE; Nesland JM
Histol Histopathol; 2012 Oct; 27(10):1315-25. PubMed ID: 22936450
[TBL] [Abstract] [Full Text] [Related]
14. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract] [Full Text] [Related]
15. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis.
Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
Oncologist; 2011; 16(2):155-64. PubMed ID: 21266401
[TBL] [Abstract] [Full Text] [Related]
16. Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and her2 expression.
Abdelzaher E; El-Gendi SM; Yehya A; Gowil AG
Br J Neurosurg; 2011 Dec; 25(6):707-13. PubMed ID: 20979437
[TBL] [Abstract] [Full Text] [Related]
17. A meta-analysis on the association of her-2 overexpression with prognosis in human osteosarcoma.
Li YG; Geng X
Eur J Cancer Care (Engl); 2010 May; 19(3):313-6. PubMed ID: 19709164
[TBL] [Abstract] [Full Text] [Related]
18. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Kai K; Nishimura R; Arima N; Miyayama H; Iwase H
Int J Clin Oncol; 2006 Dec; 11(6):426-33. PubMed ID: 17180510
[TBL] [Abstract] [Full Text] [Related]
19. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
Schoppmeyer K; Frühauf N; Oldhafer K; Seeber S; Kasimir-Bauer S
Oncol Rep; 2006 Feb; 15(2):449-54. PubMed ID: 16391868
[TBL] [Abstract] [Full Text] [Related]
20. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the her2- and Topoisomerase IIalpha-status of the primary tumor?
Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
[TBL] [Abstract] [Full Text] [Related]
[Next]
